Mahdieh Mehrab Mohseni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mahdieh Mehrab Mohseni has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Zeinab Shirvani-Farsani
Department of Cell and Molecular Biology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran
3 shared publications - Maryam Naseroleslami
Department of Cellular and Molecular Biology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
2 shared publications - Mohammad Taheri
Institute of Human Genetics, Jena University Hospital, Jena, Germany; Urology and Nephrology Research Center, Research Institute for Urology and Nephrology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications - Seyedeh Morvarid Neishabouri
Department of Psychiatric, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications - Afzal Shamsi
Tehran University of Medical Sciences
1 shared publication - Azra Kenarkoohi
Zoonotic Diseases Research Center Ilam University of Medical Sciences Ilam Iran
1 shared publication
Latest Publications
- Open Access
- 8 December 2025
- Published by Taylor & Francis in Epigenetics
- Vol. 20 (1) , 2599650
Anesthetic-induced epigenetic alterations: mechanisms and long-term clinical implications
This review explores how anesthetic agents influence epigenetic mechanisms such as DNA methylation, histone modifications, and non-coding RNA expression, and their lasting clinical effects. Common anesthetics, including propofol, isoflurane, sevoflurane, and local or regional agents, trigger epigenetic alterations. Preclinical research, especially in developing and aging brains, ties these changes to neurodevelopmental delays, cognitive decline, and shifts in immune and metabolic processes. While clinical studies are ongoing, accumulating evidence reveals that anesthesia triggers both transient and persistent epigenetic modifications, with potential links to postoperative cognitive dysfunction, prolonged inflammation, and altered developmental trajectories. Pediatric and elderly patients show heightened susceptibility due to brain plasticity or diminished resilience. Leveraging epigenetic knowledge could pave the way for tailored anesthesia approaches, reducing long-term risks. Moreover, emerging evidence suggests intergenerational transmission of these epigenetic changes via germline reprogramming, potentially affecting neurodevelopment and disease susceptibility in offspring. Future studies should prioritize large-scale human trials, detailed mechanistic insights, and identification of epigenetic biomarkers to guide safer anesthetic development. This review highlights anesthesia's broader systemic consequences, extending beyond immediate cognitive impacts, and underscores its relevance to personalized medicine.
- 8 December 2025
- Published by Taylor & Francis in Epigenetics
- Vol. 20 (1) , 2599650
Open AccessAnesthetic-induced epigenetic alterations: mechanisms and long-term clinical implications
This review explores how anesthetic agents influence epigenetic mechanisms such as DNA methylation, histone modifications, and non-coding RNA expression, and their lasting clinical effects. Common anesthetics, including propofol, isoflurane, sevoflurane, and local or regional agents, trigger epigenetic alterations. Preclinical research, especially in developing and aging brains, ties these changes to neurodevelopmental delays, cognitive decline, and shifts in immune and metabolic processes. While clinical studies are ongoing, accumulating evidence reveals that anesthesia triggers both transient and persistent epigenetic modifications, with potential links to postoperative cognitive dysfunction, prolonged inflammation, and altered developmental trajectories. Pediatric and elderly patients show heightened susceptibility due to brain plasticity or diminished resilience. Leveraging epigenetic knowledge could pave the way for tailored anesthesia approaches, reducing long-term risks. Moreover, emerging evidence suggests intergenerational transmission of these epigenetic changes via germline reprogramming, potentially affecting neurodevelopment and disease susceptibility in offspring. Future studies should prioritize large-scale human trials, detailed mechanistic insights, and identification of epigenetic biomarkers to guide safer anesthetic development. This review highlights anesthesia's broader systemic consequences, extending beyond immediate cognitive impacts, and underscores its relevance to personalized medicine.
- Open Access
- 2 June 2024
- Published by Wiley in Health Science Reports
- Vol. 7 (6) , e2152
Are miR‐26a and miR‐26b microRNAs potent prognostic markers of gestational diabetes?
Background: Gestational diabetes mellitus is a common public health problem, accompanied by complications for the mother and fetus. So, introducing new biomarkers to identify early diabetes is essential. As serum miRNAs are potentially appropriate markers, we investigated miR‐26a and miR‐26b expression levels in pregnant women with and without gestational diabetes.Method: Demographic and clinical characteristics of 40 gestational diabetic patients and 40 healthy controls were assessed. The expression level of miR‐26a and miR‐26b microRNAs was measured by real‐time PCR. Statistical analysis was done with GraphPad Prism software (version 8.4.3).Result: The findings of this study showed that the expression level of miR‐26a and miR‐26b increased in women with gestational diabetes compared with healthy pregnant women, but the increase in expression was only significant for miR‐26a (p < 0.05).Conclusion: According to the statistical and ROC curves, we suggest miR‐26a as a potential biomarker for the early diagnosis of gestational diabetes mellitus.
- 2 June 2024
- Published by Wiley in Health Science Reports
- Vol. 7 (6) , e2152
Open AccessAre miR‐26a and miR‐26b microRNAs potent prognostic markers of gestational diabetes?
Background: Gestational diabetes mellitus is a common public health problem, accompanied by complications for the mother and fetus. So, introducing new biomarkers to identify early diabetes is essential. As serum miRNAs are potentially appropriate markers, we investigated miR‐26a and miR‐26b expression levels in pregnant women with and without gestational diabetes.Method: Demographic and clinical characteristics of 40 gestational diabetic patients and 40 healthy controls were assessed. The expression level of miR‐26a and miR‐26b microRNAs was measured by real‐time PCR. Statistical analysis was done with GraphPad Prism software (version 8.4.3).Result: The findings of this study showed that the expression level of miR‐26a and miR‐26b increased in women with gestational diabetes compared with healthy pregnant women, but the increase in expression was only significant for miR‐26a (p < 0.05).Conclusion: According to the statistical and ROC curves, we suggest miR‐26a as a potential biomarker for the early diagnosis of gestational diabetes mellitus.
- 25 April 2024
- Published by Elsevier in Advances in Medical Sciences
- Vol. 69 (2) , 231-237
The oxidative stress-associated long non-coding RNAs in pancreatic cancer
- 25 April 2024
- Published by Elsevier in Advances in Medical Sciences
- Vol. 69 (2) , 231-237
The oxidative stress-associated long non-coding RNAs in pancreatic cancer
- Open Access
- 1 January 2024
- Published by Apex Publishing in Iranian Biomedical Journal
- Vol. 28 (1) , 15-22
Simvastatin-Loaded Nanoniosome Protects H9c2 Cells from Oxygen-Glucose Deprivation/Reperfusion Injury by Downregulating Inflammation
Background: Simvastatin (SIM) has anti-inflammatory and antioxidant properties against cardiac ischemia/reperfusion injury (I/RI). However, it suffers from low bioavailability and a short half-life. Nanoniosomes are novel drug delivery systems that may increase SIM effectiveness. The present research evaluates the impact of SIM-loaded nanoniosomes on the oxygen-glucose deprivation/reperfusion (OGD/R) injury model of ...
- 1 January 2024
- Published by Apex Publishing in Iranian Biomedical Journal
- Vol. 28 (1) , 15-22
Open AccessSimvastatin-Loaded Nanoniosome Protects H9c2 Cells from Oxygen-Glucose Deprivation/Reperfusion Injury by Downregulating Inflammation
Background: Simvastatin (SIM) has anti-inflammatory and antioxidant properties against cardiac ischemia/reperfusion injury (I/RI). However, it suffers from low bioavailability and a short half-life. Nanoniosomes are novel drug delivery systems that may increase SIM effectiveness. The present research evaluates the impact of SIM-loaded nanoniosomes on the oxygen-glucose deprivation/reperfusion (OGD/R) injury model of ...
- 14 November 2023
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 39 (2) , 313-320
Abnormal expression of long non-coding RNAs RMRP, CTC-487M23.5, and DGCR5 in the peripheral blood of patients with Bipolar disorder
Long non-coding RNAs (lncRNAs) have been recently considered as one of the regulatory mechanisms of the nervous system. Hence, lncRNAs may be considered diagnostic biomarkers for bipolar disorder (BD). We aimed to investigate the expression of RMRP, CTC-487M23.5, and DGCR5 lncRNAs in bipolar patients. The levels of these three lncRNAs were measured in peripheral blood mononuclear cells (PBMCs) of 50 BD patients and 50 healthy subjects by real-time PCR. Moreover, we performed a ROC curve analysis between the gene expression and some clinical features of BD patients. Significant upregulation of RMRP and CTC-487M23.5 and no significant change in levels of DGCR5 was observed in BD individuals compared with controls. Also, we found upregulation of RMRP and downregulation of CTC-487M23.5 and DGCR5 in females with BD. The areas under the ROC curve (AUC) for RMRP and CTC-487M23.5 lncRNAs were 0.80 and 0.61, respectively. There was no significant correlation between the expression of these three lncRNAs and clinical features in PBMCs of BD patients. These results suggest a role for RMRP and CTC-487M23.5 in the pathogenesis of bipolar disorder. Moreover, the peripheral expression of these two lncRNAs might be beneficial as potential biomarkers for BD.
- 14 November 2023
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 39 (2) , 313-320
Abnormal expression of long non-coding RNAs RMRP, CTC-487M23.5, and DGCR5 in the peripheral blood of patients with Bipolar disorder
Long non-coding RNAs (lncRNAs) have been recently considered as one of the regulatory mechanisms of the nervous system. Hence, lncRNAs may be considered diagnostic biomarkers for bipolar disorder (BD). We aimed to investigate the expression of RMRP, CTC-487M23.5, and DGCR5 lncRNAs in bipolar patients. The levels of these three lncRNAs were measured in peripheral blood mononuclear cells (PBMCs) of 50 BD patients and 50 healthy subjects by real-time PCR. Moreover, we performed a ROC curve analysis between the gene expression and some clinical features of BD patients. Significant upregulation of RMRP and CTC-487M23.5 and no significant change in levels of DGCR5 was observed in BD individuals compared with controls. Also, we found upregulation of RMRP and downregulation of CTC-487M23.5 and DGCR5 in females with BD. The areas under the ROC curve (AUC) for RMRP and CTC-487M23.5 lncRNAs were 0.80 and 0.61, respectively. There was no significant correlation between the expression of these three lncRNAs and clinical features in PBMCs of BD patients. These results suggest a role for RMRP and CTC-487M23.5 in the pathogenesis of bipolar disorder. Moreover, the peripheral expression of these two lncRNAs might be beneficial as potential biomarkers for BD.
- Open Access
- 17 June 2023
- Published by Maad Rayan Publishing Company in Medical Journal of Tabriz University of Medical Sciences
- Vol. 45 (3) , 111-123
Cardioprotective effects of simvastatin‑loaded nano‑niosomes on cardiomyocytes in cardiac ischemia
Background. Cardiac ischemia is the major cause of morbidity and mortality which can be increased by Statins. This study aimed to increase the effectiveness of simvastatin in the form of niosomes. Methods. In this study, 25 male Wistar rats were divided into 5 groups: control, ischemia (induced by closed LAD), ischemia receiving nano-niosomes, ischemia receiving simvastatin, and ischemia receiving simvastatin-loaded nano-niosomes. One month after the drug injection, RNA was extracted from the heart tissue of the studied groups, cDNA was synthesized, and a real-time PCR test was performed using specific primers. SPSS 21.0 software was used for statistical analysis. Analysis of variance was used to investigate the effect of the interventions, and Tukey's post hoc test was used to investigate a significant difference (P<0.05) between the control groups and other groups as well as between intervention groups. Results. Apoptosis and autophagy increased significantly in the ischemia group compared to the control group (P<0.05). In the simvastatin-loaded nano-niosomes group, compared to the simvastatin group, apoptosis and autophagy showed a significant decrease (P<0.05), and also in both simvastatin-loaded nano-niosomes and simvastatin group, compared to the control group, apoptosis and autophagy showed a significant decrease. (P<0.05). Conclusion. Simvastatin is an effective drug in the recovery of cardiac ischemia, but the main problem in using simvastatin is its instability and degradability, and the use of its niosomes form solves this problem properly. Practical Implications. Simvastatin‑loaded nano‑niosomes is more effective in reducing heart ischemia damage compared to simvastatin.
- 17 June 2023
- Published by Maad Rayan Publishing Company in Medical Journal of Tabriz University of Medical Sciences
- Vol. 45 (3) , 111-123
Open AccessCardioprotective effects of simvastatin‑loaded nano‑niosomes on cardiomyocytes in cardiac ischemia
Background. Cardiac ischemia is the major cause of morbidity and mortality which can be increased by Statins. This study aimed to increase the effectiveness of simvastatin in the form of niosomes. Methods. In this study, 25 male Wistar rats were divided into 5 groups: control, ischemia (induced by closed LAD), ischemia receiving nano-niosomes, ischemia receiving simvastatin, and ischemia receiving simvastatin-loaded nano-niosomes. One month after the drug injection, RNA was extracted from the heart tissue of the studied groups, cDNA was synthesized, and a real-time PCR test was performed using specific primers. SPSS 21.0 software was used for statistical analysis. Analysis of variance was used to investigate the effect of the interventions, and Tukey's post hoc test was used to investigate a significant difference (P<0.05) between the control groups and other groups as well as between intervention groups. Results. Apoptosis and autophagy increased significantly in the ischemia group compared to the control group (P<0.05). In the simvastatin-loaded nano-niosomes group, compared to the simvastatin group, apoptosis and autophagy showed a significant decrease (P<0.05), and also in both simvastatin-loaded nano-niosomes and simvastatin group, compared to the control group, apoptosis and autophagy showed a significant decrease. (P<0.05). Conclusion. Simvastatin is an effective drug in the recovery of cardiac ischemia, but the main problem in using simvastatin is its instability and degradability, and the use of its niosomes form solves this problem properly. Practical Implications. Simvastatin‑loaded nano‑niosomes is more effective in reducing heart ischemia damage compared to simvastatin.
- 6 June 2023
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 38 (7) , 2223-2230
Deregulation of NF-κB associated long non-coding RNAs in bipolar disorder
Long non-coding RNAs (lncRNAs) are major genetic factors whose disruption lead to many diseases, including nervous system diseases. Bipolar disorder (BD) is a neuro-psychiatric disease with no definitive diagnosis and incomplete treatment. Regarding the role of NF-κB-associated lncRNAs in the neuro-psychiatric disorders, we examined the expression of three lncRNAs, DICER1-AS1, DILC, and CHAST, in BD patients. To assess lncRNA expression in peripheral blood mononuclear cells (PBMCs) of 50 BD patients and 50 healthy individuals, Real-time PCR was used. Additionally, some clinical characteristics of BD patients were investigated via an analysis of ROC curves and correlations. Based on our results, the expression level of CHAST increased significantly in BD patients in comparison with healthy people, in BD men compared with healthy men, as well as in BD women in comparison with control females (p < 0.05). A similar increase in expression was observed for DILC and DICER1-AS1 lncRNAs in female patients compared with healthy women. Whereas compared to healthy men, DILC was decreased in diseased men. Based on the results of the ROC curve, the area under the curve (AUC) for CHAST lncRNA was 0.83 with a P value of 0.0001. So, the expression level of CHAST lncRNA could play a role in the pathobiology of the BD and be considered a good putative biomarker for individuals with bipolar disorder.
- 6 June 2023
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 38 (7) , 2223-2230
Deregulation of NF-κB associated long non-coding RNAs in bipolar disorder
Long non-coding RNAs (lncRNAs) are major genetic factors whose disruption lead to many diseases, including nervous system diseases. Bipolar disorder (BD) is a neuro-psychiatric disease with no definitive diagnosis and incomplete treatment. Regarding the role of NF-κB-associated lncRNAs in the neuro-psychiatric disorders, we examined the expression of three lncRNAs, DICER1-AS1, DILC, and CHAST, in BD patients. To assess lncRNA expression in peripheral blood mononuclear cells (PBMCs) of 50 BD patients and 50 healthy individuals, Real-time PCR was used. Additionally, some clinical characteristics of BD patients were investigated via an analysis of ROC curves and correlations. Based on our results, the expression level of CHAST increased significantly in BD patients in comparison with healthy people, in BD men compared with healthy men, as well as in BD women in comparison with control females (p < 0.05). A similar increase in expression was observed for DILC and DICER1-AS1 lncRNAs in female patients compared with healthy women. Whereas compared to healthy men, DILC was decreased in diseased men. Based on the results of the ROC curve, the area under the curve (AUC) for CHAST lncRNA was 0.83 with a P value of 0.0001. So, the expression level of CHAST lncRNA could play a role in the pathobiology of the BD and be considered a good putative biomarker for individuals with bipolar disorder.